Mood Emot 2022 Jul; 20(2): 23-30   https://doi.org/10.35986/me.2022.20.2.23
Where is the Mechanistic Target of Rapamycin Signaling Pathway in Depression?
Jung An Lee , MD
Department of Psychiatry, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea
Correspondence to: Jung An Lee, MD
Department of Psychiatry, Haeundae Paik Hospital, Inje University College of Medicine, 875 Haeun-daero, Haeundae-gu, Busan 48108, Korea
TEL +82-51-797-3303 FAX +82-51-797-0298 E-mail bluesilver27@naver.com ORCID https://orcid.org/0000-0001-9106-3805
Received: July 8, 2022; Accepted: July 19, 2022; Published online: July 31, 2022.
© Korean Society for Affective Disorders. All rights reserved.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Although the pathophysiology of depression has not been clearly elucidated yet, the mTOR (mechanistic target of rapamycin) signaling pathway has recently taken an increasingly important position in the pathophysiology of depression. In this review, preclinical and clinical studies of depression related to the mTOR signaling pathway will be summarized to explore the current position of mTOR in depression. Because the role of mTOR in the mechanism of the antidepressant effect of ketamine has been attracting attention, related studies will also be reviewed. Summarizing these studies, this review would like to suggest the basis and future direction for treatment and research of depression.
Keywords: Mechanistic target of rapamycin; Depression; Ketamine


  • Search

This Article

Archives